Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD2 | P13995 | 8/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9610905 | 0.88 | MTHFD2 (0.53) | MTHFD2MAPTPDE10AGPR119PARP1 | |
| SCHEMBL415705 | 0.84 | MTHFD2 (0.47) | MTHFD2MAPTPDE10A | |
| SCHEMBL31516387 | 0.82 | MTHFD2 (0.57) | MTHFD2KITPARP1TNKS2PARP2 | |
| SCHEMBL23972307 | 0.81 | KIT (0.41) | MTHFD2MAPTKITGBA1NAMPT | |
| SCHEMBL416075 | 0.80 | PDE10A (0.52) | MAPTGBA1PDE10AGPR119 | |
| SCHEMBL28647996 | 0.80 | PARP1 (0.47) | MTHFD2MAPTPDE10APARP1TNKS2 | |
| SCHEMBL26602815 | 0.78 | MTHFD2 (0.43) | MTHFD2MAPTKITPDE10APARP1 | |
| SCHEMBL2456754 | 0.77 | SPR (0.46) | MTHFD2MAPTNAMPTPARP1TNKS2 | |
| SCHEMBL415027 | 0.77 | PDE10A (0.70) | GBA1PDE10A | |
| SCHEMBL25381827 | 0.76 | PARP1 (0.44) | MTHFD2MAPTPARP1TNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2467382-B1 | AMINO TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2434885-B1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2434885-B1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8492392-B2 | Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492392-B2 | Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492392-B2 | Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2467382-A1 | AMINO TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20120136012-A1 | AMINO TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120065211-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20120065211-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20120065211-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| WO-2010138430-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138430-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065211-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | PDE12, PDE4A, PDE5A | MTHFD2 214/4885MAPT 1064/4885KIT 4487/4885 |
| US-20120136012-A1 | AMINO TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | PDE12, PDE4A, PDE10A | MTHFD2 152/4885MAPT 1101/4885KIT 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.